Functional Magnetic Resonance Imaging (fMRI) of Anosognosia in Amnestic Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)
FMRI of Anosognosia in Amnestic MCI and AD: Focus on Cortical Midline Structures
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53705
- William S Middleton VA Hospital GRECC
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Amnestic MCI:
- Observation of memory decline by informant.
- Mini Mental Status Exam (MMSE) score between 24 and 30.
- Objective memory impairment on neuropsychological tests.
- Intact functional abilities, and 4) no diagnosis of dementia.
AD:
- A diagnosis of probable AD according with the NINDS-ADRDA and DSM-IV diagnostic criteria.
- MMSE score between 16 and 27. All AD patients will have capacity to provide informed consent as judged by the referring physician.
Exclusion Criteria:
- MRI incompatibility; history of neurologic disease (including prior loss of consciousness of more than 10 minutes); prior neurosurgery; or chronic medical diseases (such as poorly controlled diabetes, renal disease, or poorly controlled hypertension).
- Excluded medications include neuroleptics, short or long acting nitrates, and Warfarin.
- Other exclusions include: less than 10 yrs of education; Hachinski scale of 4 or more; first language other than English; poor visual or auditory acuity; pregnancy.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Controls
The control group have to be medically and cognitively healthy(MMSE ≥ 28; Hopkins Verbal Memory Test-Revised raw score within 1.5 SD of normative values for age and gender).
These individuals are recruited from the community and all attempts will be made to match them on age and education to individuals recruited for groups of AD and aMCI.
|
|
amnestic Mild Cognitive Impairment
Participants who have expressed interest to take part in the study.
A consensus from the study clinicians regarding the diagnosis will be required before a subject is enrolled.
The criteria for MCI include 1) observation of memory decline by informant, 2) Mini Mental Status Exam (MMSE) score between 24 and 30, 3) objective memory impairment on neuropsychological tests, 3) intact functional abilities, and 4) no diagnosis of dementia.
|
|
Alzheimer's disease
Patients with probable Alzheimer's disease according with the NINDS-ADRDA and DSM-IV diagnostic criteria.
An additional criterion is a MMSE score between 16 and 27.
All AD patients must have capacity to provide informed consent as judged by the referring physician.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Neurocognitive Disorders
- Neurodegenerative Diseases
- Dementia
- Tauopathies
- Cognition Disorders
- Perceptual Disorders
- Alzheimer Disease
- Cognitive Dysfunction
- Agnosia
Other Study ID Numbers
Other Study ID Numbers
- HSC-2008-0090
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.